Whereas neurofilaments light chain (NfL) currently represent the most prominent example of a biomarker being implemented as an end point in ALS clinical trials,23 many other wet, imaging, and neurophysiology biomarkers are under active investigation.14 The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.